Giá của Senhwa Biosciences, Inc. là bao nhiêu (6492)

Giá của Senhwa Biosciences, Inc. (6492) là $1.11

Mũ thị trường của Senhwa Biosciences, Inc. là gì (6492)

Giới hạn thị trường của Senhwa Biosciences, Inc. (6492) là $100.55M

Lịch sử giá Senhwa Biosciences, Inc. (6492)

Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and headquartered in New Taipei City, Taiwan, specializes in advancing novel drugs and targeted therapeutic agents. The firm is actively progressing several clinical programs. Its compound CX-5461 is undergoing various investigations, including a Phase I, open-label study assessing dose escalation, safety, pharmacokinetics, and pharmacodynamics of its intravenous administration in individuals with advanced blood cancers. CX-5461 is also in a Phase I trial for solid cancerous growths, as well as a Phase Ib expansion study focusing on solid tumors characterized by BRCA2 and/or PALB2 genetic mutations. Furthermore, CX-5461 is being evaluated in a Phase I trial alongside pidnarulex and talazoparib for patients battling metastatic castration-resistant prostate cancer. Beyond CX-5461, Senhwa is also developing several variations of CX-4945. CX-4945-CCA is participating in a Phase I/II clinical investigation, combined with gemcitabine, for treating cholangiocarcinoma. CX-4945-BCC is the subject of a Phase I, multi-center, open-label study, examining its safety and pharmacodynamic profile when administered orally twice daily to patients with advanced basal cell carcinoma. The company's CX-4945-MB compound is being explored in a Phase I/II and surgical study, led by a pediatric brain tumor consortium, for the management of recurrent SHH medulloblastoma. Lastly, CX-4945-AV06 is currently in a Phase II, double-blind, randomized, controlled study, designed to evaluate its safety and effectiveness in hospitalized adults afflicted with COVID-19.

Năm	Hiệu suất
2026 (TTM)	9.09%
2025	-0.30%
2024	-22.02%
2023	-15.51%
2022	-44.72%
2021	-53.30%
2020	275.09%
2019	-9.86%
2018	3.54%
2017	-60.65%
2016	1.24%
2015	74.07%
2014	0.00%

Năm

Hiệu suất

2026 (TTM)

9.09%

2025

-0.30%

2024

-22.02%

2023

-15.51%

2022

-44.72%

2021

-53.30%

2020

275.09%

2019

-9.86%

2018

3.54%

2017

-60.65%

2016

1.24%

2015

74.07%

2014

0.00%

Công ty	Giá cổ phiếu	Thay đổi 1năm%	Quốc gia
Vertex Pharmaceuticals Incorporated VRTX.US	$547.71	38.62%	US
Argenx SE ARGX.US	$1.04K	58.06%	NL
Moderna, Inc. MRNA.US	$145.75	437.43%	US
CSL Limited CSL.AX	$118.70	-15.60%	AU
Lonza Group AG LONN.SW	$770.19	8.98%	CH

Công ty

Giá cổ phiếu

Thay đổi 1năm%

Quốc gia